IceCure Medical (ICCM) reported a third-quarter loss of $0.40 per share, well ahead of the -$0.83 consensus for a 51.8% earnings surprise. The rest of the report was weaker. Revenue of $0.82 million missed the $0.85 million consensus by 3.1% and fell 3.1% year over year. Earnings fell 566.7% from the prior-year quarter. The bottom-line beat says more about a larger share base than about operating improvement. Issued shares rose from about 2.4 million at year-end to roughly 5.6 million by September 30, which spreads a growing dollar loss across many more shares. That is the central tension: a headline beat sits on top of a quarter in which sales slipped, margins compressed and cash burn accelerated.
The release is built around a nine-month view that blurs the third-quarter slowdown. Nine-month revenue rose 26% to $2.6 million. That growth rate has slowed sharply from the 45% pace reported through the first half. Third-quarter revenue of about $0.8 million came in below both the prior-year quarter and the roughly $0.9 million per quarter booked in Q1 and Q2 2026. Gross profit rose 22% to $762,000 for nine months, but the implied Q3 gross margin was about 27%, down from roughly 33% a year earlier.
Operating expenses kept climbing:
- R&D rose to $6.6 million, driven by the ChoICE Study.
- Sales and marketing rose to $3.7 million.
- The nine-month net loss widened to $13.0 million from $10.8 million.
The U.S. growth claim also deserves a careful read. The release cites 83% U.S. sales growth but in one bullet also says U.S. sales "doubled." Even taken at face value, strong U.S. growth did not prevent total revenue from declining in the quarter.
The conference call reinforced the impression of a company stepping back from the "inflection point" framing of earlier calls. There were real positives:
- **U.S. footprint:** coverage expanded to 21 states, with new reps in Florida and Southern California.
- **ChoICE Study:** the post-marketing study grew from two contracted sites last quarter to four, and the first patients were treated in October.
- **International:** China approved ProSense as a Class III device, and IceCure signed an exclusive Netherlands distributor.
- **2027 outlook:** management offered informal commentary pointing to "healthy double-digit growth." It was not formal guidance.
Much of the call, however, consisted of walking back prior expectations:
- **ChoICE enrollment:** the 80-patients-by-March-2027 target was not reaffirmed, and the CEO said he is unsure the 400-patient, three-year goal is achievable. He also raised the possibility of seeking an FDA extension.
- **Japan:** Terumo's PMDA submission slipped from mid-2026 to the first half of 2027.
- **Health Canada:** a decision moved from "before year-end" to roughly two to four months out.
- **Installed base:** management withheld an update on the U.S. installed base, last cited at about 30 active sites.
- **Sales team:** the team stands at roughly 7-9 people, against a prior plan to triple it by year-end.
The balance sheet is the most pressing risk. Cash fell to $8.2 million from about $12 million at June 30, despite an $8.5 million raise in Q2. That implies roughly $3.8 million of burn in a single quarter. Nine-month operating cash outflow reached $12.6 million, up from $9.6 million a year earlier. At the current burn rate, the cash balance covers only about two quarters. Further financing, and further dilution, looks difficult to avoid. Gross margins are moving the wrong way and revenue has stalled, so the business is not closing that gap on its own.
The market had already priced in much of the damage. Shares closed at $0.83 ahead of the report, down 72.3% from the $3.00 open after the August release. The stock sits about 50% below its 200-day moving average of $1.66 and roughly 76% below the inter-earnings high of $3.40, set on the day of the last report. It has bounced about 28% off the $0.65 low set on November 5. Investor sentiment improved dramatically, from a maximally negative -1.0 to roughly neutral at -0.08. That reads more like exhausted pessimism after a collapse than renewed conviction. Most Earnings Whispers trend readings remain negative, with only momentum turning positive alongside that recent rebound.
The bottom line is that IceCure's EPS beat is a share-count artifact rather than evidence of operating progress. The quarter showed declining revenue, thinner gross margins, faster cash consumption, and a string of delayed or abandoned milestones on ChoICE enrollment, Japan, Canada and sales-force build-out. The China approval, a broader U.S. footprint and a first look at 2027 growth keep the long-term adoption story alive. The near-term setup, however, will be defined by financing needs and by whether management can restore credibility on the timelines it just pushed out.